key: cord-0755952-1js3mgq3
authors: Fumagalli, Marcilio Jorge; Castro-Jorge, Luiza Antunes; Fraga-Silva, Thais Fernanda de Campos; de Azevedo, Patrick Orestes; Capato, Carlos Fabiano; Rattis, Bruna Amanda Cruz; Hojo-Souza, Natália Satchiko; Floriano, Vitor Gonçalves; de Castro, Julia Teixeira; Ramos, Simone Gusmão; da Fonseca, Benedito Antônio Lopes; Bonato, Vânia Luiza Deperon; Gazzinelli, Ricardo Tostes; Figueiredo, Luiz Tadeu Moraes
title: Protective Immunity against Gamma and Zeta Variants after Inactivated SARS-CoV-2 Virus Immunization
date: 2021-12-04
journal: Viruses
DOI: 10.3390/v13122440
sha: c121de1327def4e274fa895dd35b63cc5f990af6
doc_id: 755952
cord_uid: 1js3mgq3

The persistent circulation of SARS-CoV-2 represents an ongoing global threat due to the emergence of new viral variants that can sometimes evade the immune system of previously exposed or vaccinated individuals. We conducted a follow-up study of adult individuals that had received an inactivated SARS-CoV-2 vaccine, evaluating antibody production and neutralizing activity over a period of 6 months. In addition, we performed mice immunization with inactivated SARS-CoV-2, and evaluated the immune response and pathological outcomes against Gamma and Zeta variant infection. Vaccinated individuals produced high levels of antibodies with robust neutralizing activity, which was significantly reduced against Gamma and Zeta variants. Production of IgG anti-S antibodies and neutralizing activity robustly reduced after 6 months of vaccination. Immunized mice demonstrated cellular response against Gamma and Zeta variants, and after viral infection, reduced viral loads, IL-6 expression, and histopathological outcome in the lungs. TNF levels were unchanged in immunized or not immunized mice after infection with the Gamma variant. Furthermore, serum neutralization activity rapidly increases after infection with the Gamma and Zeta variants. Our data suggest that immunization with inactivated WT SARS-CoV-2 induces a promptly responsive cross-reactive immunity response against the Gamma and Zeta variants, reducing COVID-19 pathological outcomes.

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) emerged in late 2019 in Wuhan, China [1] . SARS-CoV-2 is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic, a human respiratory disease characterized by dry cough, headache, fever, severe pneumonia, and shortness of breath that can rapidly progress to respiratory can infect common laboratory mice, leading to increased lung viral load and moderate lung lesions [37, 38] . This viral adaptation is partially attributed to changes in key residues at the receptor binding domain (RBD) of S protein, including N501Y, which is also present in mouse-adapted SARS-CoV-2 [39] .

One of the concerns with the emergence of more infectious variants is the effectiveness of currently used COVID-19 vaccines against the new variants, which may evade vaccine-induced immunity. The cross-protection conferred by vaccination with inactivated WT SARS-CoV-2 against Gamma or Zeta variants using the murine model has not been evaluated. Therefore, we investigated anti-SARS-CoV-2 antibodies titers in individuals vaccinated with the CoronaVac vaccine, an inactivated viral vaccine at 1, 3, and 6 months after the second dose. In addition, we established an animal model to evaluate protective immune response induced by immunization with inactivated WT SARS-CoV-2 against the Gamma and Zeta variants, evaluating for antibody production, tissue viral load, inflammatory cytokine expression, lung histopathological analysis, and serum neutralizing activities.

Blood samples were collected from healthy volunteers that had been vaccinated with the CoronaVac vaccine (Sinovac Life Sciences, Beijing, China). Eligibility criteria were a minimal age of 18 years old, no history of COVID-19 disease, and CoronaVac vaccination. Volunteers were recruited at Virology Research Center and Clinics Hospital, both from Ribeirão Preto Medical School. The cohort (n = 10) was composed of researchers and medical workers aged 29-64 (average of 44) consisting of 6 males and 4 females ( Figure 1A ). Samples were collected before the first dose and 1, 3, and 6 months after the second dose.

Three different SARS-CoV-2 lineages were used in this study, the WT (Genbank access MT126808.1), Gamma (P.1) (GISAID: EPI_ISL_2499748), and Zeta (P.2) (GISAID: EPI_ISL_770561), which were isolated from clinical samples in Brazil [23, 40] . Viral stocks were propagated in Vero E6 cells (ATCC CRL-1586) cultured with Dulbecco's Modified Eagle's Medium (DMEM) (Vitrocell, Campinas, São Paulo, Brazil) containing 1% penicillin/streptomycin and 2% fetal bovine serum (FBS), and maintained at 37 • C and 5% CO 2 . After 3 days postinfection, the cell culture supernatant was collected, clarified by low-speed centrifugation (300× g for 10 min), and stored at −80 • C. Viral titration was performed by plaque-forming unit (PFU) assay as previously described [40] .

For immunization, inactivated WT SARS-CoV-2 was prepared on the basis of previously described studies [41] . Briefly, Vero E6 cells were propagated in a T-150 flask, the cell culture supernatant was removed; then, cells were washed twice with phosphate-buffered saline (PBS), inoculated with WT SARS-CoV-2, and incubated for 1 h under gently rocking for viral adsorption. As a negative control, only culture media were used (Mock). After incubation, DMEM with 2% FBS was added, and cells were incubated at 37 • C and 5% CO 2 until observation of cytopathic effects (>50%). The cell culture supernatant was collected, clarified by low-speed centrifugation, and incubated with β-propiolactone (Sigma-Aldrich, St. Louis, MO, USA) at 0.05% (v/v) for 20 h at 4 • C under gentle rocking for viral inactivation. The solution was ultracentrifuged at 170,000× g for 1 h, and the viral pellet was resuspended in 2 mL of PBS. To hydrolyze residual β-propiolactone, the inactivated virus was incubated for 2 h at 37 • C on a warm bath. For in vitro cell stimulation, viral particles from the cell culture supernatant were heat-inactivated by incubating at 60 • C for 2 h on a warm bath. Total protein concentration was determined by Bradford assay using Quick Start Bradford Dye Reagent (Biorad, Hercules, CA, USA), and samples were kept at −80 • C until usage. To evaluate viral inactivation, samples were inoculated on Vero E6 cells, incubated at 37 • C and 5% CO 2, and monitored daily for cytopathic effects. 

Six-week-old female C57BL/6 mice were used for immunization twice, at 0 and 14 days with 10 5 PFUs of inactivated WT SARS-CoV-2 or Mock with 30% (v/v) of hydroxide aluminum adjuvant by intramuscular route. Blood samples were collected at 14 and 28 days after initial immunization by facial bleeding. The blood was centrifuged, and the sera were collected for humoral immune response evaluation. For cellular immune response analysis, splenocytes were collected after 28 days of vaccination and stimulated in vitro with SARS-CoV-2 antigens. Some immunized mice were infected with 7 × 10 4 PFUs of WT SARS-CoV-2, and Gamma or Zeta variants by intranasal route at 28 days after the initial immunization. Three days after the viral infection, blood samples were collected for antibody measurement and neutralizing assays. Mice were euthanized, and the lungs were collected for analysis. The superior right lobe was gently perfused with a 10% formaldehyde solution, kept in the same solution for 7 days, processed using the automated PT05 TS processor (Lupetec, São Carlos, São Paulo, Brazil), embedded in paraffin, sectioned at 4 µm thickness, and stained with Harris's hematoxylin and eosin (H&E) for histopathological analysis. The left lung was collected in Roswell Park Memorial Institute (RPMI) 1640 Medium (Sigma-Aldrich, St. Louis, Missouri USA) containing 1% penicillin/streptomycin and 5% FBS, and processed for flow cytometry analysis. The middle and inferior right lobes were weighed and homogenized with PBS (1:5 w/v) using a 5 mm stainless steel bead (Qiagen, Germantown, Maryland, USA) and a TissueLyser LT (Qiagen, Germantown, MD, USA), (50 Hz for 5 min), centrifuged at 10,000× g for 10 min, and the supernatant was collected and used for viral load measurement by plaque assay, qRT-PCR, and cytokine quantification.

For plaque assay, one day before infection, 5 × 10 4 Vero E6 cells were plated in a 48-well plate and cultivated overnight in DMEM containing 10% FBS. On the next day, samples were serially diluted in DMEM from 10 −1 to 10 −6 , cell culture supernatant was removed, and viral dilutions were inoculated in duplicate. Plates were incubated for 1 h at room temperature under gentle rocking to allow for viral adsorption. Next, 500 µL of prewarmed overlay media (DMEM containing 2% (w/v) carboxymethylcellulose and 2% FBS) was added to each well, and plates were incubated for 5 days at 37 • C and 5% CO 2 to allow for plaque formation. Then, cells were fixed for 2 h with 4% formaldehyde solution and stained with 1% naphthol blue-black (Sigma-Aldrich, St. Louis, MO, USA) solution for 1 h for plaque visualization.

RNA was extracted with TRIzol (Thermo Fisher Scientific, Waltham, Massachusetts, USA) reagent with 20 mg of lung homogenate, according to the manufacturer's recommendation. For viral RNA quantification, qRT-PCR was performed using TaqMan Fast Virus 1-Step Mix (Applied Biosystems, Waltham, MA, USA) according to the manufacturer's recommendations. SARS-CoV-2 primers and probe were designed according to a previously reported protocol (REF). They target a 100 bp region from RNAdependent RNA polymerase gene (RdRp) of all three SARS-CoV-2 variants (forward: 5 -GTGAAATGGTCATGTGTGGCGG-3 ; reverse: 5 -CAAATGTTAAAAACACTATTAGCATA-3 ; and probe: '5-FAM-CAGGTGGAACCTCATCAGGAGATGC-BHQ1-3 ). Reactions were performed using a StepOnePlus Real-Time PCR system (Applied Biosystems, Waltham, Massachusetts, USA). Each sample was analyzed in duplicate, and results were compared to a standard relative curve using viral stocks from cell culture with a known titer in PFU/mL.

To determine the neutralizing activity of mouse and human sera, plaque reduction neutralization assays with a 50% cutoff (PRNT 50 ) were performed. Briefly, 5 × 10 4 Vero E6 cells were plated in a 48-well plate in DMEM containing 10% FBS, and cultivated overnight at 37 • C and 5% CO 2 . Then, serum samples were heat-inactivated at 56 • C for 1 h, serially diluted from 1:5 to 1:160 (human samples) or 1:10 to 1:320 (mice samples) in DMEM, and mixed with 10 2 PFU of different SARS-CoV-2 variants. As a positive control, media only were used instead of the sample. The virus-serum mixture was incubated for 1 h at 37 • C to allow for antibody-virus-binding complex formation. Subsequently, the cell culture supernatant was removed, and the antibody-virus mixtures were inoculated to each well in duplicate. For viral adsorption, the plates were incubated for 1 h under gentle rocking at room temperature. The residual viral inoculum was removed, and a prewarmed overlay medium was added to each well. To allow for plaque formation, plates were incubated for 4 days (WT) or 5 days (Gamma and Zeta variants) at 37 • C and 5% CO 2 . For plaque counting, cells were fixed for 2 h with a 4% formaldehyde solution and stained with 1% Naphthol blue-black (Sigma-Aldrich, St. Louis, Missouri, USA) solution for 1 h. Neutralization activity was determined by reduction in plaque formation from the sample-virus mixture when compared to the positive control. The area under the curve (AUC) was calculated using Prism v.8.0.2 (GraphPad, San Diego, CA, USA).

Antibody production against SARS-CoV-2 were determined using recombinant spike (S) and nucleocapsid (N) proteins as capture antigens in the ELISA format. ELISA plates were coated overnight with 50 µL of S or N protein diluted at 4 µg/mL in carbonatebicarbonate pH 9. 

Spleens were collected from C57BL/6 mice 28 days after immunization and processed for lymphoproliferation assay. Briefly, 2 × 10 5 splenocytes were stimulated with 10 µg of heat-inactivated viral antigens for 5 days at 37 • C and 5% CO 2 . Phytohemagglutinin (Vitrocell, Campinas, São Paulo, Brazil) was used as positive control, and lymphoproliferation was determined using CellTiter-Glo (Promega, Madison, WI, USA) according to the manufacturer's recommendations. The luminescence signal was normalized with mock stimuli, and the immunized group signal was normalized with the mock immunized group.

Cytokine profile was determined on the third day after viral infection with the three viral lineages in mouse lungs using the Cytometric Bead Array (CBA) Mouse Th1/Th2/Th17 Cytokine kit (BD Biosciences, Franklin Lakes, NJ, USA). Procedures were performed according to manufacturer instructions, and samples were acquired on BD FACSCanto (BD Biosciences, Franklin Lakes, NJ, USA) and analyzed using FCAP Array v3.0 (BD Biosciences, Franklin Lakes, NJ, USA).

The middle and inferior lobes were collected and digested with collagenase (2.2 mg/mL) and DNAse (0.055 mg/mL) (Roche, Basel, Switzerland). Samples were stained for viability with FVS780 and cell subpopulations with CD45-PE-Cy7 (30-F11), CD3-FITC (145-2C11), CD4-BB700 (RM4-5), CD8-PE (53-6.7), and CD25-APC (PC61). Samples were acquired in FACS Melody (BD Biosciences, Franklin Lakes, New Jersey, USA), and analyses were performed in FlowJo software (BD Biosciences, Franklin Lakes, NJ, USA).

Statistical analysis was conducted using GraphPad Prism 8.0.2 software (GraphPad, San Diego, CA, USA). Grubb's test was applied to detect and remove possible outliers, and the Kolmogorov-Smirnoff test was used to verify data distribution. Comparison between two distinct groups was determined using an unpaired, two-tailed Student's t-test with a 95% confidence interval. For multiple-group comparisons, one-or two-way analysis of variance (ANOVA) was used, followed by the post hoc test specified in each figure legend. Statistical differences were considered significant when p value < 0.05.

To evaluate the immunogenicity of immunization with inactivated SARS-CoV-2, blood samples were collected from individuals before vaccination, and 1, 3, and 6 months after the second vaccine dose with CoronaVac ( Figure 1A) . Detection of IgM antibodies increased after initial vaccination, but nonsignificant changes were observed after 6 months ( Figure 1B) . Production of anti-S IgG was observed after 1 month of vaccination; however, a 1.5-and 5-fold decrease in IgG levels was observed after 3 and 6 months, respectively ( Figure 1C ). Unchanged levels of N-specific IgG and IgM antibodies were observed before and after vaccination. A decrease in neutralizing activities was observed at 1, 3, and 6 months of vaccination with a significant reduction in cross-neutralizing titers for the Gamma and Zeta variants (Figure 2A-D) . Collectively, these results demonstrate that vaccination with inactivated SARS-CoV-2 is able to induce S-specific IgG and IgM antibodies, but with a reduction over 6 months, especially in cross-neutralizing titers against the Gamma and Zeta variants. Nonlinear regression curves generated with a maximum of 1000 interactions and 95% confidence interval. Error bars delimited by colors. Multiple comparisons were performed by two-way ANOVA followed by Sidak's post hoc test. Asterisks, significance difference compared to 1-month group. * p < 0.05; ** p < 0.001; *** p < 0.0001. (D) PRNT50 neutralizing titers of WT SARS-CoV-2, and Gamma and Zeta variants using sera from vaccinated individuals collected at different time points, indicated by black (prevaccination), purple (1 month), turquoise (3 months), and red (6 months). Multiple comparisons were performed by one-way ANOVA followed by Tukey's post hoc test. * p < 0.05; ** p < 0.001. PRNT50 = 50% plaque reduction neutralization test; n.s.= not statistically significantly; LOD = limit of detection.

To assess the immunogenicity of inactivated WT SARS-CoV-2, we set up a two-dose immunization protocol using C57BL/6 mice. Blood, spleen, and lung samples were collected before and after viral infection ( Figure 3A ). We observed an increased production of IgG antibodies against the S protein at 14 and 28 days after immunization with an increased ratio of approximately 10-and 30-fold, respectively, and an undetectable production of antibodies to the N protein ( Figure 3B ). Furthermore, we observed an increased lymphoproliferation of spleen cells from immunized mice after 5 days of stimulation with total viral antigens of the WT, Gamma, and Zeta lineages, but no significant proliferation differences were observed among them ( Figure 3C ). These results show that immunization with inactivated WT SARS-CoV-2 induces the production of anti-S antibodies, and cross-reactive cellular response to Gamma and Zeta variants. Spleen organs collected on day 28 and used for lymphoproliferation assay. Three days after infection, mice were euthanized and the lungs collected for analysis. (B) IgM and IgG antibodies production anti-N and anti-S after 14, and 28 days of initial immunization were detected by indirect ELISA. AUC from immunized mice was normalized with AUC from the same mice before infection. (C) Lymphoproliferation assay was performed with splenocytes from immunized and nonimmunized mice stimulated for 5 days with 10 µg of inactivated viral antigens of WT SARS-CoV-2, Gamma or Zeta viral lineage. Statistical analysis was conducted by one-way ANOVA followed by Tukey's post hoc test. n.s. = not statistically significant; AUC = area under curve; IgM = immunoglobulin M; IgG = immunoglobulin G.

Next, we assessed the cytokine profile and protective efficacy of immunization with inactivated WT SARS-CoV-2 in C57BL/6 mice against Gamma and Zeta variant infection. Viral RNA levels quantified by qRT-PCR were practically undetectable in lungs from mice immunized and infected with WT SARS-CoV-2, but no significant changes were observed in either immunized or nonimmunized groups after infection with the Gamma or Zeta variant ( Figure 4A ). However, viral load in mouse lungs measured by plaque assay was significantly reduced in immunized mice after infection with Gamma or Zeta variants ( Figure 4B ). IL-6 production in immunized mice was reduced to almost undetectable levels after the infection with the WT lineage, and reduced twofold after infection with the Gamma variant, while the Zeta variant induced less production of IL-6 and nonsignificant differences between immunized and nonimmunized mice ( Figure 4C ). TNF production in immunized mice was reduced 10-fold after infection with the WT or Zeta variant; no significant changes were observed in immunized or nonimmunized mice after infection with the Gamma variant ( Figure 4D ). Levels of IL-10, IL-4, IL-2, IL-17, and IFN-γ were under the detection limit. 

Histological analysis showed that WT SARS-CoV-2 infection induced mild congestion and a moderate mixed inflammatory infiltrate (mononuclear cells and scarce neutrophils) in the lungs of immunized or nonimmunized mice ( Figure 5A ). However, nonimmunized mice infected with the Gamma variant showed more representative lesions, characterized by a diffuse alveolar thickening due to a moderate mixed inflammatory infiltrate when compared to the immunized group, which showed just a mild peribronchovascular inflammatory infiltrate. On the other hand, the nonimmunized group infected with the Zeta variant exhibited a reduced inflammatory infiltrate in the alveolar septum, more evident only in the peribronchovascular area, while the immunized group presented a clear reduction with mild inflammatory focus. Control groups showed preserved lung architecture. No significant changes were observed for CD3 + , CD4 + , and CD8 + T lymphocyte subpopulations percentages in immunized or nonimmunized mouse lungs after 3 days of infection ( Figure 5B ). 

The evaluation of anti-S IgG antibody production 3 days after infection with WT SARS-CoV-2, and Gamma and Zeta variants in immunized mice showed no significant differences among the groups ( Figure 6A ). However, the viral infection induced an increase in neutralizing titers for the three mouse groups ( Figure 6B ). Sera from immunized mice before the infection showed reduced neutralizing capacity against the Gamma variant compared to WT lineage ( Figure 6C ). However, 3 days after viral infection, the neutralizing profile rapidly shifted, and the three mouse groups showed a similar profile of neutralizing activity ( Figure 6D ). These results indicate that anti-S IgG antibody titers do not significantly change after viral infection, but neutralizing activities rapidly increase, demonstrating a fast cross-reactive immune response against the Gamma and Zeta variants. ) . Multiple comparisons performed by ordinary one-way ANOVA followed by Tukey's post hoc test. (B) Neutralizing titers in PRNT50 of immunized (n = 4) and nonimmunized (n = 3) mouse sera before and after viral infection with WT SARS-CoV-2 (n = 6), Gamma (n = 5), or Zeta (n = 5) lineages. (C,D) Neutralizing profile against WT SARS-CoV-2, Gamma, or Zeta lineages from immunized mouse sera before (n = 4) and 3 days after (n = 6, for each group) viral infection. Nonlinear regression curves generated with a maximum of 1000 interactions and 95% confidence interval. Error bars delimited by colors. Multiple comparisons performed by two-way ANOVA followed by Tukey's post hoc test. * p < 0.05; ** p < 0.001. AUC = area under curve; PRNT50 = 50% plaque reduction neutralization test; LOD = limit of detection; n.s. = not statistically significant.

In this study, we evaluated immune response after immunization with CoronaVac, an inactivated SARS-CoV-2-based vaccine. In agreement with a clinical trial study of CoronaVac, we observed an induction of similar levels of neutralizing activity with the production of anti-S IgG antibodies after 1 month of vaccination. However, when compared to other commercially available vaccines, such as BNT162b2 (Pfizer), ChAdOx1 (AstraZeneca), and Ad26.COV2.S (Johnson & Johnson), the neutralizing titers were apparently lower [21, [42] [43] [44] . We observed a significant decrease in IgG levels in the months after vaccination. This result was expected considering that inactivated vaccines induce a weaker immune response due to antigenicity loss during inactivation. A recent preprint study suggested that a third dose of CoronaVac would be recommended to efficiently recall specific immune responses against SARS-CoV-2 [45] . In agreement, we showed that neutralizing activity against WT SARS-CoV-2 is considerably reduced over the course of 6 months in recipients of CoronaVac. A similar pattern of neutralization decrease was observed against the Gamma and Zeta variants, but with a significant reduction from the first month after vaccination, probably due to immune evasion of the variants [28, 30] .

Previous studies described that immunization with inactivated SARS-CoV-2 induces a robust production of antibodies and cellular immune response [21, 46, 47] . Likewise, we showed that mice immunized with inactivated WT SARS-CoV-2 produced anti-S IgG antibodies. Furthermore, mouse spleen cell stimulation with inactivated viral antigens induced lymphoproliferation with no significant differences among different viral antigens, suggesting the existence of cellular immune response to conserved epitopes. These results agree with previous reports showing the production of anti-S IgG antibodies in immunized mice within 1 to 6 weeks, and undetectable differences in lymphocyte activation with viral antigens from different variants [14, 31] .

High viral load in humans was correlated with increased disease severity and a higher risk of death by COVID-19 [48, 49] . In our study, we detected viral RNA in the lung tissue from mice infected by any of the three SARS-CoV-2 lineages. However, only the WT-infected group showed a significant reduction in SARS-CoV-2 RNA levels after immunization. On the other hand, viral load measured by plaque assay was detected only in mice infected with the Gamma or Zeta variant, indicating different susceptibility degrees of C57BL/6 mice to infection. The discrepancy between the detection of viral RNA and viable virus indicates the existence of conservative factors, such as phagocytic cells, which can conserve the viral genetic material in lung tissue for longer periods after infection, even in the absence of viable virus. The viral load from immunized mice showed nearly 2-log reduction and undetectable levels upon infection with the Gamma and Zeta variants, respectively, indicating the induction of protective immunity.

A key characteristic of severe COVID-19 is the dysregulation of inflammatory pathways with the increased production of cytokines such as interleukine-6 (IL-6) and tumor necrosis factor-α (TNF-α) [50, 51] . In our study, infection with WT SARS-CoV-2, and Gamma and Zeta variants induced IL-6 and TNF production in nonimmunized mice and variable expression levels according to lineage, reinforcing the different susceptibility of mice to viral infection. Increased levels of IL-6 and TNF were significantly associated with the severity of lung injury in COVID-19 pneumonia. In addition, circulating IL-6 was the independent predictor of lung-injury severity [52] . Consistent with more intense inflammation observed in nonimmunized mice infected with the Gamma variant, we found higher levels of IL-6 in this mice group. Undetectable levels of IL-6 and TNF-α, consistent with a reduction in the pulmonary inflammatory infiltrate, showed that immunization was effective in mice infected with WT SARS-CoV-2 or the Zeta variant. Although less effective for the Gamma variant, IL-6 levels showed a significant reduction after immunization. Collectively, these data suggest that immunization with inactivated WT SARS-CoV-2 virus is able to induce a cross-protective immune response against Gamma and Zeta variant infection.

Previous studies demonstrated that the Gamma variant can escape the serum neutralizing antibodies of convalescent patients or individuals vaccinated with Oxford-AstraZeneca, Pfizer/BioNTech, or CoronaVac vaccines [28, 30] . Here, we showed that, although neutralizing antibody titers were lower for the Gamma and Zeta variants before infection, there was a significant increase as early as 3 days after viral infection, reaching comparable levels to those observed for WT SARS-CoV-2. This induction of neutralizing antibody produc-tion against SARS-CoV-2 variants suggests the existence of cross-reactive immunological memory, which is triggered to rapidly respond against the new viral infection.

In agreement, previous reports described that fully vaccinated individuals with inactivation-based vaccines that were subsequently infected by different SARS-CoV-2 variants (vaccine breakthrough) produce high levels of humoral response and serum neutralizing activities, indicating a probable protective immune recall induced by the infection [53] [54] [55] . In this context and considering our data in the murine model, fully vaccinated individuals with inactivated WT SARS-CoV-2 who had been infected with the Gamma or Zeta variant may rapidly cross-respond to viral infection and produce efficient neutralizing antibodies, which may be critical for protection against COVID-19. This idea is further supported by a recent study that reported two cases of SARS-CoV-2 infection by the Gamma variant in elderly individuals who received CoronaVac but developed only mild symptoms [56] .

Taken together, vaccination with inactivated WT SARS-CoV-2 virus is able to induce immunological cross-protection against the Gamma and Zeta variants. Individuals vaccinated with CoronaVac produce elevated levels of anti-S antibodies with significant decay over time. Therefore, it is possible that booster vaccine doses may be necessary to ensure adequate population protection and pandemic control, and further efforts to improve vaccine immunogenicity would be greatly valuable. Immunized mice that had been infected with the variants showed reduced pathological outcomes with a rapid increase in serum neutralizing activity, suggesting the existence of cross-reactive immunological memory to conserved epitopes. Thus, a continuous elucidation of the immunological mechanisms and clinical outcomes of convalescent and vaccinated individuals against new variants is extremely important as a countermeasure against COVID-19.

A Novel Coronavirus from Patients with Pneumonia in China

Clinical Characteristics of Coronavirus Disease 2019 in China

World Health Organization. Coronavirus Disease (COVID-19) Dashboard

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques

A Thermostable mRNA Vaccine against COVID-19

SARS-CoV-2 Vaccines

Inactivated poliovirus vaccine: Past and present experience

Safety of trivalent inactivated influenza vaccines in adults: Background for pandemic influenza vaccine safety monitoring

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: Interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled

Development of an inactivated vaccine candidate for SARS-CoV-2

Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice

SARS-CoV-2 vaccines in development

COVID-19 Vaccine Market Dashboard

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): Interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: A double-blind, randomised, controlled, phase 1/2 clinical trial

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

SARS-CoV-2 variants, spike mutations and immune escape

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus

Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: An immunological study

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Antibody evasion by the P.1 strain of SARS-CoV-2

Negligible impact of SARS-CoV-2 variants on CD4 (+) and CD8 (+) T cell reactivity in COVID-19 exposed donors and vaccinees

SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

Animal models for COVID-19

Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology

Receptor Recognition by the Novel Coronavirus from Wuhan: An Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

Common laboratory mice are susceptible to infection with SARS-CoV2 beta variant

The B1.351 and P.1 variants extend SARS-CoV-2 host range to mice

Rapid adaptation of SARS-CoV-2 in BALB/c mice: Novel mouse model for vaccine efficacy

SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network

Propagation, Inactivation, and Safety Testing of SARS-CoV-2. Viruses

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

Immunogenicity and safety of a third dose, and immune persistence of CoronaVac vaccine in healthy adults aged 18-59 years: Interim results from a double-blind, randomized, placebo-controlled phase 2 clinical trial

SARS-CoV-2-specific T cell immunity to structural proteins in inactivated COVID-19 vaccine recipients

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial

Kinetics of viral load and antibody response in relation to COVID-19 severity

SARS-CoV-2 viral load is associated with increased disease severity and mortality

Dysregulation of Immune Response in Patients With Coronavirus

Immune characteristics of severe and critical COVID-19 patients

Association between cytokine profiles and lung injury in COVID-19 pneumonia

SARS-CoV-2 infection in fully vaccinated individuals of old age strongly boosters the humoral immune response. Front

Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection After Vaccination with Adenovirus-Vectored and Inactivated Vaccines

Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152

Case Study of Two Post Vaccination SARS-CoV-2 Infections with P1 Variants in CoronaVac Vaccinees in Brazil

Informed Consent Statement: All participants provided written informed consent before inclusion in the study, and all procedures were conducted according to good clinical practices and clinical data collection.

The authors declare no conflict of interest.